With advancements of systemic therapies, including ADT combined with androgen receptor pathway inhibitors (ARPIs) and chemotherapy, the median overall survival (OS) for de novo metastatic prostate cancer has improved significantly over the past two decades, although it remains approximately 30 months [13]. This evidence concerns the gene AR and metastatic prostate carcinoma.